Sanuwave Health initiated with a Buy at Roth Capital

Roth Capital analyst Kyle Bauser initiated coverage of Sanuwave Health (SNWV) with a Buy rating and $49 price target Sanuwave is a medical technology company focused on the commercialization of its UltraMIST system, a non-contact, low-frequency ultrasound therapy platform used for the treatment of complex wounds, the analyst tells investors in a research note. The firm sees a “compelling” growth profile in a “large and untapped” market for the company. Roth sees upside from Sanuwave’s new lower-cost applicator and “under-utilized” capacity.